BRPI0906311A2 - "uso de um muramil dipeptídeo reticulado em uma micropartícula e composição farmacêutica dotada de atividade neoplásica" - Google Patents

"uso de um muramil dipeptídeo reticulado em uma micropartícula e composição farmacêutica dotada de atividade neoplásica"

Info

Publication number
BRPI0906311A2
BRPI0906311A2 BRPI0906311A BRPI0906311A BRPI0906311A2 BR PI0906311 A2 BRPI0906311 A2 BR PI0906311A2 BR PI0906311 A BRPI0906311 A BR PI0906311A BR PI0906311 A BRPI0906311 A BR PI0906311A BR PI0906311 A2 BRPI0906311 A2 BR PI0906311A2
Authority
BR
Brazil
Prior art keywords
microparticle
cross
pharmaceutical composition
muramyl dipeptide
neoplastic activity
Prior art date
Application number
BRPI0906311A
Other languages
English (en)
Inventor
Frank B Gelder
Gillian Alison Webster
Original Assignee
Innate Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Therapeutics Ltd filed Critical Innate Therapeutics Ltd
Publication of BRPI0906311A2 publication Critical patent/BRPI0906311A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6062—Muramyl peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0906311A 2008-04-01 2009-04-01 "uso de um muramil dipeptídeo reticulado em uma micropartícula e composição farmacêutica dotada de atividade neoplásica" BRPI0906311A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ56709608 2008-04-01
PCT/NZ2009/000049 WO2009123481A1 (en) 2008-04-01 2009-04-01 Compositions and methods for treatment of neoplastic disease

Publications (1)

Publication Number Publication Date
BRPI0906311A2 true BRPI0906311A2 (pt) 2016-07-05

Family

ID=41135763

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906311A BRPI0906311A2 (pt) 2008-04-01 2009-04-01 "uso de um muramil dipeptídeo reticulado em uma micropartícula e composição farmacêutica dotada de atividade neoplásica"

Country Status (8)

Country Link
US (2) US9415061B2 (pt)
EP (1) EP2271352A4 (pt)
JP (1) JP5662309B2 (pt)
CN (1) CN102149391A (pt)
AU (1) AU2009232504B2 (pt)
BR (1) BRPI0906311A2 (pt)
CA (1) CA2719216C (pt)
WO (1) WO2009123481A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009123480A1 (en) * 2008-04-01 2009-10-08 Virionyx Corporation Ltd Anti-infective agents and uses thereof
WO2009123481A1 (en) * 2008-04-01 2009-10-08 Virionyx Corporation Ltd Compositions and methods for treatment of neoplastic disease
NZ571665A (en) * 2008-09-30 2011-01-28 Innate Therapeutics Ltd Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles
JP5922104B2 (ja) * 2010-05-27 2016-05-24 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッドＳｈｅｎｚｈｅｎ Ｓａｌｕｂｒｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ デューアル機能性の抱合体の化学合成及び抗腫瘍及び抗腫瘍転移作用
WO2013049220A1 (en) * 2011-09-30 2013-04-04 University Of Southern California Novel vaccination strategies or therapeutic treatment for influenza virus
EP2968557A4 (en) * 2013-03-13 2016-09-28 Health Research Inc IMPROVING VACCINES
AU2016202146A1 (en) * 2015-10-06 2017-04-20 Innate Immunotherapeutics Limited Compositions and methods for protection and/or repair of the nervous system
WO2017059486A1 (en) * 2015-10-06 2017-04-13 Innate Immunotherapeutics Limited Compositions and methods for the treatment of epilepsy
WO2017070731A1 (en) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions and methods for the treatment of alzheimer's disease
CN106589055B (zh) * 2016-11-03 2020-07-28 清华大学 取代的细胞酰二肽类化合物及其制备方法和用途
CN111235106B (zh) * 2019-08-30 2022-08-05 武汉大学 一种靶向肿瘤细胞的Aptamer-CD3+T细胞及其构建方法与应用
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177263A (en) * 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
US4397844A (en) * 1978-02-24 1983-08-09 Ciba-Geigy Corporation Antigen derivatives and processes for their preparation
US4574058A (en) * 1978-02-24 1986-03-04 Ciba-Geigy Corporation Antigen derivatives and processes for their preparation
US4357322A (en) * 1980-07-29 1982-11-02 Syntex (U.S.A.) Inc. Method of preventing, reducing or inhibiting inflammation
US5208022A (en) * 1988-05-19 1993-05-04 State University Of New York (Suny) Non-malignant cells coupled to adjuvants and their use in a method to induce anti-tumor immunity
US4994440A (en) * 1989-02-13 1991-02-19 Creaven Patrick J Method for the treatment of renal cell carcinoma
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US6953573B1 (en) * 1993-03-17 2005-10-11 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
GB9320820D0 (en) * 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
NZ334941A (en) 1996-10-10 2000-11-24 Probe Internat Methods for treating infections using proteins which induce an immune response in one animal species but not in another
US20070269406A1 (en) * 2005-12-14 2007-11-22 Ichim Thomas E Transcatheter tumor immunoembolization
US20090081157A1 (en) 2006-01-09 2009-03-26 Richard Syd Kornbluth Immunostimulatory Combinations for Vaccine Adjuvants
US8603978B2 (en) * 2006-12-01 2013-12-10 The United States of America, as represented by the Secretary, Department of Health and Humand Services Use of muramyl dipeptide (MDP) for treating inflammation
WO2009123481A1 (en) * 2008-04-01 2009-10-08 Virionyx Corporation Ltd Compositions and methods for treatment of neoplastic disease

Also Published As

Publication number Publication date
AU2009232504B2 (en) 2013-04-04
AU2009232504A1 (en) 2009-10-08
WO2009123481A1 (en) 2009-10-08
EP2271352A4 (en) 2014-01-15
US20160354424A1 (en) 2016-12-08
US9415061B2 (en) 2016-08-16
US9950025B2 (en) 2018-04-24
CA2719216A1 (en) 2009-10-08
EP2271352A1 (en) 2011-01-12
US20110165250A1 (en) 2011-07-07
CA2719216C (en) 2016-01-19
CN102149391A (zh) 2011-08-10
JP5662309B2 (ja) 2015-01-28
JP2011516471A (ja) 2011-05-26

Similar Documents

Publication Publication Date Title
NO20085420L (no) Farmasøytisk formulering med fenylefrin og preparater for absorpsjon i tykktarmen
SI2185552T1 (sl) Dipeptoidna predzdravila in njihova uporaba
BRPI0811180A2 (pt) Uso de probióticos ou uma mistura dos mesmos para a preparação de composição farmacêutica utilizável em um ambiente pré e/ou pós-cirúrgico.
PL2476435T3 (pl) Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych
GB2437875B (en) Skin care composition comprising L-carnosine and N-acetylcysteine
PL2054405T3 (pl) Nowe pochodne biarylobenzimidazolu i zawierająca je kompozycja farmaceutyczna
BRPI0813955A2 (pt) composições terapêuticas e o uso das mesmas
BRPI0813017A2 (pt) " formulação líquida e uso de uma formulação líquida "
IL188732A (en) Use of ibuprofen and famotidine in the preparation of medicaments
AP2657A (en) Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy
EP2037917A4 (en) Pharmaceutical composition comprising amlodipine and losartan
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
EP2123276A4 (en) A pharmaceutical composition containing pyrazine derivative and method for using a pyrazine derivative in combination
GB2443336B (en) Spiruchostatin analogues and their medicinal use
BRPI1006666A2 (pt) " composição farmacêutica e uso de uma composição farmacêutica"
ZA200904061B (en) Fuel composition and its use
GB0523576D0 (en) Drug composition and its use in therapy
EP2341047A4 (en) CYCLOHEXANE DERIVATIVE AND ITS PHARMACEUTICAL USE
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
DE602008005137D1 (de) Chinolonverbindung und pharmazeutische zusammensetzung
IL195493A0 (en) Combination preparations comprising bifeprunox and l-dopa
SI1858481T1 (sl) Oftalmološki sestavki in njihova uporaba
IL199178A0 (en) Aminoalcohol derivatives and their therapeutic use
PT2117519E (pt) Composição farmaceutica compreendendo tramadol e cetoprofeno
BRPI0615630A2 (pt) composição farmacêutica, e, uso de sertindol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]